Menu Back toS15-Lessens-from-Experiences-Using-MidNet-for-PV

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S15] Lessens from Experiences Using MidNet for PV

Session Chair(s)

Yoshiaki  Uyama, PhD, RPh

Yoshiaki Uyama, PhD, RPh

  • Director, Office of Medical Informatics and Epidemiology
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
So far, there have been three cases of the use of MID-NET, a government-owned database which has become available since April 2018. These three companies are invited to talk about their experience of using MID-MET from various perspectives such as data accumulation, data analysis, information delivery and discuss issues in using the database. In the panel, a representative of MID-NET devision of PMDA will also invited and the future perspective of the utilization of MID-NET for pharmacovigilance as well as the issues to overcome for a full utilization of the database.


Katsuhiko  Ichimaru

Overview of Utilization of MID-NET

Katsuhiko Ichimaru

  • Director of MID-NET Operation and Management
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Kei  Sagawa

Practice of MID-NET Use in Post-Marketing Database Study

Kei Sagawa

  • Pharmacovigilance, Safety and Risk Management Department
  • Daiichi Sankyo Co., Ltd., Japan
Makoto  Miyazaki

Utilization of MID-NET from Pharmacovigilance Perspective

Makoto Miyazaki

  • Safety Strategy Execution 2, Pharmacovigilance & Risk Management
  • MSD K.K., Japan
Shintaro  Hiro, PhD

Recommendations on Feasibility Assessment to Leverage MID-NET

Shintaro Hiro, PhD

  • Manager, Data Science & Analytics Japan Lead, Clinical Statistics
  • Pfizer R&D Japan, Japan